Summary We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22 patients with advanced ovarian cancer. Twenty-one patients (95.4%) received six cycles of treatment: of these, 13 (61.9%) were also able to repeat cycles every 14 days as planned. Marrow toxicity was similar to that observed during conventional treatments. No severe mucositis or thrombocytopenia was observed. A clinical complete response was observed in 9 out of 16 evaluable patients (56.2%).
The importance of dose intensity in chemotherapy, i.e. the amount of drug delivered per unit of time, has been stressed in several experimental and clinical contributions after early retrospective analyses by Hryniuk and Bush (1984) and Hryniuk (1987) underlined the relationship between planned dose intensity and response rate in breast cancer. Based on another retrospective study (Levine and Hryniuk, 1987) , ovarian cancer appears to be a particularly suitable model for intensification of chemotherapy: however, prospective data about the use of intensified regimens in this disease are still scarce.
In the present study we have evaluated the feasibility of an increase of the dose intensity of a polychemotherapy regimen commonly used in ovarian cancer (PEC; cisplatin, epidoxorubicin and cyclophosphamide) . Such increase was obtained reducing the intervals between cycles, with the use of granulocyte colony-stimulating factor (filgrastim, G-CSF) as prophylactic supportive treatment.
Patients and methods
To be eligible for the trial, patients had to have histological diagnosis of epithelial ovarian carcinoma; previous adequate cytoreductive surgery was required, with FIGO III -IV staging; serum creatinine, serum bilirubin and haemogram had to be within normal limits. Informed consent was obtained from all patients.
Chemotherapy consisted of cisplatin 50 mg m-2, epidoxorubicin 60 mg m-2 and cyclophosphamide 600 mg m-2, all administered intravenously on day 1 every 14 days for six cycles. Filgrastim was administered subcutaneously from day 4 to day 9 between cycles.
In the case of incomplete marrow recovery (WBC < 3000 mm-' and/or platelets < 100.000 mm-3) on day 1 of the cycle, chemotherapy was delayed for 1 week or until complete marrow recovery. In the case of haemoglobin levels of 9 g dl-' or less a blood transfusion was supplied and chemotherapy was not postponed. In the case of a platelet count of 50 000 mm-3 or less, detected at any time during therapy, a 50% reduction of the doses of all drugs was planned for the remaining courses.
The primary aim of the study was to evaluate the feasibility of accelerated PEC treatment: the activity of the treatment was also assessed according to WHO response criteria. Toxicity was evaluated according to ECOG criteria.
Planned and total delivered dose intensity were calculated as the amount of drug (mg m-2) administered per unit of time (week), according to the indications of Hryniuk and Bush (1984) and Coppin (1987) . The planned dose intensity was 25 mg m-2 per week for cisplatin, 30 mg m-2 per week for epidoxorubicin and 300 mg m-2 per week for cyclophosphamide. For each patient, the actually delivered dose intensity (received dose intensity, RDI) was calculated as a percentage of the planned one Results Twenty-two patients entered the trial. The main characteristics of patients are shown in Table I . One patient refused to continue the trial after two cycles. Twenty-one patients (95.4%) received all six cycles of PEC without any reduction in doses: of these, 13 (59.1%) also completed the treatment without delays between cycles. Two patients (9.5%) completed the treatment with a delay of 1 week (between the fifth and the sixth cycle), and four (19%) with a delay of 2 weeks (1 week between the fourth and the fifth cycle and 1 week between the fifth and the sixth cycle). A delay greater than 2 weeks (respectively of 4 and 5 weeks) occurred in two patients (9.5%), one of which was suffering grade III acute emesis and delayed emesis that caused a poor compliance to chemotherapy, while the second patient delayed the cycles because of psychological distress.
The (Kaye, 1995) . The Italian cooperative group GONO has compared two regimens of PEC using cisplatin at the dose of 50 mg 2 and 100 mg-2 respectively . The high-dose cisplatin regimen seemed significantly more toxic but not more active, although definitive results are not available.
On the whole, the possibility of obtaining clinical benefits from an increase of chemotherapy dose intensity in ovarian cancer still seems controversial. Future studies should also examine aspects such as quality of life and cost/benefit considerations: other interesting data may derive from the exploration of much higher dose intensity increases, obtainable for example with peripheral blood stem cell reinfusion.
